Irsogladine

Irsogladine

SCHEMBL62215

Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 1/20 1.00
PDE4D Q08499 1/20 1.00
NPC1 O15118 4/20 0.53
RAB9A P51151 3/20 0.53
AGPAT2 O15120 3/20 0.51
RECQL P46063 1/20 0.49
ALDH1A1 P00352 2/20 0.48
HSP90AA1 P07900 3/20 0.47
HSP90AB1 P08238 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CDK9 P50750 2/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NFKB1 P19838 1/20 0.47
CASP3 P42574 1/20 0.47
CDK5 Q00535 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
CDK5R1 Q15078 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Irsogladine SCHEMBL29517870 1.00 HTR2B (1.00) HTR2BPDE4DNPC1RAB9AAGPAT2
SCHEMBL8412370 0.91 HTR2B (0.83) HTR2BPDE4DNPC1RAB9AAGPAT2
Irsogladine SCHEMBL29518346 0.86 HTR2B (0.73) HTR2BPDE4DNPC1RAB9AAGPAT2
Irsogladine SCHEMBL440934 0.86 HTR2B (0.73) HTR2BPDE4DNPC1RAB9AAGPAT2
Irsogladine SCHEMBL3308315 0.86 HTR2B (0.73) HTR2BPDE4DNPC1RAB9AAGPAT2
Irsogladine SCHEMBL8447523 0.86 HTR2B (0.73) HTR2BPDE4DNPC1RAB9AAGPAT2
SCHEMBL8413392 0.85 HTR2B (0.73) HTR2BPDE4DNPC1RAB9AAGPAT2
Irsogladine SCHEMBL28287178 0.84 HTR2B (0.71) HTR2BPDE4DNPC1RAB9AAGPAT2
SCHEMBL9566485 0.84 HTR2B (0.72) HTR2BPDE4DNPC1RAB9ARECQL
SCHEMBL9566554 0.84 HTR2B (0.72) HTR2BPDE4DNPC1RAB9AAGPAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9741 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
US-12478627-B2 Irsogladine for the treatment of eosinophilic gastrointestinal diseases EPITHELION SCIENCE BIOTECH, S.L. (ES) 2025-11-25 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-11903992-B2 Composition comprising lidocaine, l-carnosine and dexpanthenol CELLIX BIO PRIVATE LIMITED (IN) 2024-02-20 US claimed
EP-3980020-B1 IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES EPITHELION SCIENCE BIOTECH S L (ES) 2023-08-23 EP claimed
WO-2022190030-A1 A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES AVACA PHARMA PRIVATE LIMITED (IN) 2022-09-15 WO claimed
WO-2022157587-A1 A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL CELLIX BIO PRIVATE LIMITED (IN) 2022-07-28 WO claimed
US-20220233629-A1 COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL CELLIX BIO PRIVATE LIMITED (IN) 2022-07-28 US claimed
US-20220226333-A1 IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES EPITHELION SCIENCE BIOTECH, S.L. (ES) 2022-07-21 US claimed
WO-2000061549-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-6093748-A APPLYING TO AN AREA OF SKIN FROM WHICH REDUCED HAIR GROWTH IS DESIRED A DERMATOLOGICALLY ACCEPTABLE COMPOSITION CONTAINING A NON-STEROIDAL SUPPRESSOR OF ANGIOGENESIS AHLUWALIA GURPREET S (US) 2000-07-25 US claimed
WO-2000010552-A2 USE OF ANTI-ANGIOGENIC AGENTS FOR INHIBITING VESSEL WALL INJURY GLOBAL VASCULAR CONCEPTS, INC. (US) 2000-03-02 WO claimed
EP-0812185-A2 USE OF ANGIOGENESIS SUPPRESSORS FOR INHIBITING HAIR GROWTH HANDELMAN, Joseph H. (US) 1997-12-17 EP claimed
WO-1996026712-A2 USE OF ANGIOGENESIS SUPPRESSORS FOR INHIBITING HAIR GROWTH HANDELMAN, JOSEPH, H. (US) 1996-09-06 WO claimed
US-4657907-A ANTIULCER AGENT NIPPON SHINYAKU CO., LTD. (JP) 1987-04-14 US claimed
EP-0114908-B1 FINELY PULVERIZED 2,4-DIAMINO-6-(2,5-DICHLOROPHENYL)-1,3,5-TRIAZINE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF NIPPON SHINYAKU COMPANY, LIMITED (JP) 1986-05-21 EP claimed
US-4532238-A Treating peptic ulcers NIPPON SHINYAKU CO., LTD. (JP) 1985-07-30 US claimed
EP-0114908-A1 Finely pulverized 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine and pharmaceutically acceptable acid addition salts thereof NIPPON SHINYAKU COMPANY, LIMITED (JP) 1984-08-08 EP claimed